<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235634</url>
  </required_header>
  <id_info>
    <org_study_id>REPERFUSE_8092_BO_S_2018</org_study_id>
    <nct_id>NCT04235634</nct_id>
  </id_info>
  <brief_title>Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia</brief_title>
  <acronym>REPERFUSE</acronym>
  <official_title>Evaluation of an Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia (NOMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimal invasive intra-arterial prostaglandin therapy is currently being offered as an&#xD;
      established and safe treatment approach for Non-occlusive mesenteric ischemia (NOMI). So far,&#xD;
      there are no data that prospective evaluate clinical response parameters of this method and&#xD;
      corresponding criteria for response.&#xD;
&#xD;
      The investigators are therefore planning a prospective observational study on NOMI patients&#xD;
      with the aim to collect&#xD;
&#xD;
        1. routine clinical data,&#xD;
&#xD;
        2. data from advanced angigraphic imaging and&#xD;
&#xD;
        3. data from blood biomarkers of intestinal ischemia before/at implementation of&#xD;
           intra-arterial vasodilatory therapy.&#xD;
&#xD;
      From these three data packages, the investigators hope to subsequentially derive criteria to&#xD;
      better predict response to therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>28 days following intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Serum Lactate (KEY Secondary Outcome)</measure>
    <time_frame>24 hours following intervention</time_frame>
    <description>as indicator of ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of norepinephrine dose in microgram/kg/min from baseline at 24 hours</measure>
    <time_frame>24 hours following intervention</time_frame>
    <description>as indicator of Shock reversal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>simplified NOMI score, range 0-7 points with higher scores indicating more severe NOMI</measure>
    <time_frame>immediately following first intra-arterial bolus</time_frame>
    <description>angiographic characteristics of vasodilation following Initial Prostaglandin bolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak density (PD) as measured by 2D perfusion angiography</measure>
    <time_frame>immediately following first intra-arterial bolus</time_frame>
    <description>angiographic characteristics of vasodilation following Initial Prostaglandin bolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve (AUC) as measured by 2D perfusion angiography</measure>
    <time_frame>immediately following first intra-arterial bolus</time_frame>
    <description>angiographic characteristics of vasodilation following Initial Prostaglandin bolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to peak (TTP) as measured by 2D perfusion angiography</measure>
    <time_frame>immediately following first intra-arterial bolus</time_frame>
    <description>angiographic characteristics of vasodilation following Initial Prostaglandin bolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intestinal fatty acid-binding protein (I-FABP), smooth muscle protein of 22kDa (SM22) liver fatty acid-binding protein (L-FABP)</measure>
    <time_frame>24 hours following intervention</time_frame>
    <description>markers of ischemic intestinal barrier dysfunction</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Occlusive Mesenteric Ischaemia (NOMI)</condition>
  <arm_group>
    <arm_group_label>Intra-arterial Prostglandin therapy</arm_group_label>
    <description>Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostavasin</intervention_name>
    <description>Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)</description>
    <arm_group_label>Intra-arterial Prostglandin therapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the ICU with persistent shock, intestinal failure as well as new onset&#xD;
        and progressive organ failure with a CT and angiography based diagnosis of Non-occlusive&#xD;
        mesenteric ischemia (NOMI)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - persistent shock: Norepinephrine dose &gt; 0.2ug/kg/min over &gt; 48hrs&#xD;
&#xD;
        and&#xD;
&#xD;
          -  intestinal failure: paralytic ileus &gt; 24hrs despite neostigmine therapy or&#xD;
&#xD;
          -  new onset progressive organ failure (2 out of six criteria): Norepinephrine dose&#xD;
             increase, rise in serum lactate, decrease in Horowitz index, new renal replacement&#xD;
             therapy, rise in bilirubin, rise in INR, or all of the following: rise in ALT, AST, CK&#xD;
             and LDH&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients &lt; 18 years old&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Markus Busch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for gastroenterology and hepatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Stahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for nephrology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus Stahl, MD</last_name>
    <phone>00495115327632</phone>
    <email>stahl.klaus@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Busch, MD</last_name>
    <phone>00495115327632</phone>
    <email>busch.markus@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Stahl, MD</last_name>
      <phone>00495115327623</phone>
      <email>stahl.klaus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Markus Busch, MD</last_name>
      <phone>00495115327623</phone>
      <email>busch.markus@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-occlusive mesenteric ischemia</keyword>
  <keyword>Shock</keyword>
  <keyword>Intra-arterial prostglandin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesenteric Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

